Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Qual Life Res. 2013 Feb 19;22(9):10.1007/s11136-013-0360-6. doi: 10.1007/s11136-013-0360-6

Table 1.

Sample & Clinical Characteristics at Follow-Up Interview (N=857)

Demographics N (%) or
Mean ± SD
Clinical Characteristics N (%) or
Mean ± SD
Age at Diagnosis Stage of Breast Cancer
Mean age±SD 55.29±10.31 In situ-Stage 0 193 (22%)
Marital Status Localized-Stage I 342 (40%)
Married 473 (57%) Regional-Stage II a 160 (19%)
Widowed 105(13%) Stage II b 82 (10%)
Divorced/Separated 190 (22%) Stage III a 19 (2%)
Never Married 57 (7%) Unstaged 60 (7%)
Education Adjuvant Therapy
≤ High School Graduate 218 (25%) None 274 (32%)
Some College 311 (36%) Radiation Therapy 313 (37%)
College Graduate 166 (19%) Chemotherapy 82 (9%)
Graduate School 161 (19%) Radiation Therapy and Chemotherapy 188 (22%)
Employment Status Surgery
Working 474 (57%) No Surgical Procedure 14 (2%)
Not working – leave, retired, unemployed 319 (37%) Partial Mastectomy 552 (64%)
Not working - disabled 33 (4%) Total/modified Mastectomy 290 (34%)
Income Tamoxifen at follow-up
≤ 20,000 148 (18%) No 460 (56%)
20,001 – 50,000 284 (33%) Yes 368 (44%)
50,001 – 70,000 222 (27%)
≥70,000 118 (14%)
Race/Ethnicity Lymphedema
Non-Hispanic Caucasian 506 (67%) Never 681 (79%)
Non-Hispanic African American 224 (30%) Yes, not current 49 (6%)
Non-Hispanic Other 25 (3%) Yes, current 127 (15%)
Ethnicity: Hispanic 102 (12%)
Menopausal Status Bothered by Lymphedema in Past 3 Months
Post-menopausal 628 (76%) Not at all 49 (28%)
Pre-menopausal 151 (18%) A little/ A fair amount 108 (61%)
Unclassifiable 49 (6%) Much/Very much 19 (11%)
Smoking Status BMI
Not at all (or N/A) 729 (85%) < 25 377 (44%)
Every day 71 (9%) 25–29 239 (28%)
On some days 28 (3%) ≥ 30 241 (28%)
Comorbidities SEER Site
0 215 (26%) New Mexico 457 (53%)
1–2 400 (47%) Western Washington State 177 (21%)
≥3 213 (25%) Los Angeles County 223 (26%)
# Comorbid Conditions that Limit Activities Hormone Receptors
0 618 (75%) Estrogen receptor positive (ER+) 480 (56%)
1 145 (18%) Progesterone receptor positive (PR+) 386 (45%)
2 38 (5%) Antidepressants at Follow-Up
3–4 27 (2%) Yes 128 (15%)